Examination of the impact of shifting practice from plain film mammography to digital mammography

Similar documents
Trends in stage-specific breast cancer incidence and overdiagnosis in NSW

OVERDETECTION INFORMATION IN A BREAST CANCER SCREENING DECISION AID

Breast Cancer Screening

Acknowledgments: Maureen Rice, Rachel Warren, Judy Brown, Meghan Kenny, Sharon Peck-Reid, Sarah Connor Gorber

Translating Evidence Into Policy The Case of Prostate Cancer Screening. Ruth Etzioni Fred Hutchinson Cancer Research Center

Glass Half Full, Glass Half Empty: Evidence and Perspectives on Overdiagnosis and Cancer Screening:

CONTENTS NOTE TO THE READER...1 LIST OF PARTICIPANTS...3

Otis W. Brawley, MD, MACP, FASCO, FACE

Screening Overdiagnosis. Archie Bleyer, MD Department of Radiation Medicine Knight Cancer Institute at the Oregon Health & Science University

Cite this article as: BMJ, doi: /bmj f (published 8 March 2005)

IL Balance Sheet dei programmi di screening mammografici dell Unione Europea

Breast Screening: risks if you do and risks if you don t. Stephen W. Duffy Wolfson Institute of Preventive Medicine

Prostate Cancer Screening: Risks and Benefits across the Ages

Breast Cancer Screening

Thomas Karlsson & Esa Österberg National Research and Development Centre for Welfare and Health Alcohol and Drug Research Group P.O.

WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017

Screening for Prostate Cancer with the Prostate Specific Antigen (PSA) Test: Recommendations 2014

The OECD Health Care Quality Indicators Project

THE DATABASE OF CANCER CONTROL FOR DEVELOPING GCOUNTRIES

HPV, Cancer and the Vaccination Programme

Weekly Influenza Surveillance Report. Week 11

Key outcomes for studies on breast cancer screening

Screening for Colorectal Cancer

Prostate-Specific Antigen Based Screening for Prostate Cancer Evidence Report and Systematic Review for the US Preventive Services Task Force

Screening for Abdominal Aortic Aneurysm: Systematic Review and Meta-analysis

Canadian Cochrane Network & Centre. Copyright 05/12/2009 by Phil Hahn

Advice Statement 005/18 April 2018

THE IMPACT OF DIAGNOSTIC CHANGES ON THE RISE IN THYROID CANCER INCIDENCE

European Commission Initiative on Breast Cancer (ECIBC) MEETING OF MONITORING SUBGROUP Ispra, 14 September 2016 (10:00-17:00) Minutes

Association of symptoms and interval breast cancers in the mammography-screening programme: population-based matched cohort study

Current dietary habits in Europe far from plant based eating

Diagnostic tests for autism spectrum disorder(asd) in preschool children(review)

508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender

LEBANON. WCPT COUNTRY PROFILE December 2018

Type 1 Diabetes Australian Research Impact Analysis

Rethinking Breast Cancer Screening

DENMARK. WCPT COUNTRY PROFILE December 2018

Does digital mammography suppose an advance in early diagnosis? Trends in performance indicators 6 years after digitalization

STATS Relationships between variables: Correlation

Smokefree Policies in Europe: Are we there yet?

Burden and cost of alcohol, tobacco and illegal drugs globally and in Europe

GERMANY. WCPT COUNTRY PROFILE December 2018

Deceased donation data in the UK. Paul Murphy National Clinical Lead for Organ Donation United Kingdom

BREAST CANCER SCREENING IS A CHOICE

Making Cross-Country Comparisons on Health Systems and Health Outcomes - What are the Criteria for Study Designs?

The effectiveness of breast cancer screening

25 September 2012 Early Years Pathfinder. misuse. Insert name of presentation on Master Slide. Presenter: Dr Sarah J Jones

Injecting trends in Austria including results of a systematic literature review on interventions aiming to influence the route of administration

Overdiagnosis and Overtreatment of Prostate Cancer and Breast Cancer Due to Screening

Alcohol-related harm in Europe and the WHO policy response

MENTAL HEALTH DISORDERS: THE ECONOMIC CASE FOR ACTION Mark Pearson Head of Department, OECD Health Division

Overdiagnosis of breast cancer in population screening: does it make breast screening worthless?

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009

TOMOSYNTHESIS. Daniela Bernardi. U.O. Senologia Clinica e Screening mammografico APSS Trento, Italy

Screening Mammography for Women Aged 40 to 49 Years at Average Risk for Breast Cancer

Overview of European Consumption Databases

European Experience and Perspective on Assessing Value for Oncology Products. Michael Drummond Centre for Health Economics, University of York

Urgent Medical Device Correction

Engagement in language assessment / Regions of Europe

BreastScreen Victoria tomosynthesis screening trial, Maroondah pilot: Preliminary Outcomes

Supplementary Online Content

Alcohol Prevention Day

Screening Mammography Policy and Politics. Kevin L. Piggott, MD, MPH August 29, 2015

Perspectives for information on alcohol use in the EU

IARC A UNIQUE AGENCY. Cancer research for cancer prevention

European Association of Dental Public Health Prevention of Oral Cancer

The U.S. Preventive Services Task Force (USPSTF) CLINICAL GUIDELINE

EARLY DETECTION: MAMMOGRAPHY AND SONOGRAPHY

Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement

Good Laboratory Practice. EU-Serbia screening meeting Brussels, 19 June 2014

TEDDY. Teddy Network of Excellence. Annagrazia ALTAVILLA. Ph.D. Sciences Ethics LL.M. Health Law. diterranée

Health Care Providers:

Breast tomosynthesis reduces radiologist performance variability compared to digital mammography

Overview of drug-induced deaths in Europe - What does the data tell us?

Examine breast cancer trends, statistics, and death rates, and impact of screenings. Discuss benefits and risks of screening

Results you can trust

How often should I get a mammogram?

#46: DIGITAL TOMOSYNTHESIS: What is the Data Really Showing? TERMS (AKA) WHAT IS TOMOSYNTHESIS? 3/3/2014. Digital breast tomosynthesis =

Breast cancer; screening or overdiagnosis? Questioning of a family doctor

PROGRESS ON HCQI RESEARCH AND DEVELOPMENT WORK

European Association for Cardiovascular Prevention & Rehabilitation (EACPR) A Registered Branch of the ESC

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

WCPT COUNTRY PROFILE December 2017 SWEDEN

The next best thing to fruits and vegetables

Systematic Review of Cancer Screening Literature for Updating American Cancer Society Breast Cancer Screening Guidelines

New antiretroviral agents efficacy and safety. Rilpivirine Elvitegravir Both agents with Truvada,+/- cobicistat (not in search terms)

Case study examining the impact of German reunification on life expectancy

Interval Cancers in BreastScreen Aotearoa

WCPT COUNTRY PROFILE December 2017 HUNGARY

Should I Get a Mammogram?

WCPT COUNTRY PROFILE December 2017 SERBIA

Identifying red flags when reassessing screening programmes.

Update in Breast Cancer Screening

Transcription:

Examination of the impact of shifting practice from plain film mammography to digital mammography Presented by Rachel Farber Sydney Medical School, School of Public Health The University of Sydney Page 1

Background Most breast screening programmes worldwide have replaced the use of screen-film mammography with full-field digital mammography Digital mammography Takes an electronic image of the breast Allows images to be stored and transmitted electronically Potentially decrease time between screen and results While FFDM provides significant technical and practical advantages over SFM in the provision of population screening programs, the effect of this move on health outcomes remains unclear. The University of Sydney Page 2

Review Questions In asymptomatic women attending routine breast cancer screening: 1. What impact has the transition from film mammography to digital mammography had on health outcomes? 2. What are the benefits and harms of the effect of this move as measured by detection rates and interval cancer rates? 3. If there is increased detection of cancers with the change in technology, to what extent does this reflect increased detection of clinically important cancers compared to overdiagnosed cancers? The University of Sydney Page 3

Methodology - measuring the benefits and harms Screen-detected cancers (including DCIS) Diagnosed by a positive screening result in asymptomatic women Detection rates number of women diagnosed with screen-detected breast cancer per 1000 screened women Interval cancers (including DCIS if applicable) Diagnosed after a negative screening result and before the subsequent scheduled screening Typically present clinically Interval rates number of interval cancers per 1000 screened women The University of Sydney Page 4

Methodology - measuring the benefits and harms Detection of clinically important and rapidly progressing cancers Increase in the detection rate Decrease in the interval cancer rate Detection of overdiagnosed or slow progressing cancers Increase in the detection rate No, or minimal, change in the interval cancer rate Clinically Important Cancers Overdiagnosed Cancers Detection Rate Interval Cancers Interval Cancers Interval Cancers Interval Cancers Film Digital Time Film Digital The University of Sydney Page 5

Systematic Review Collate all published data that compares SFM to FFDM drawn from the same population of: asymptomatic women who are at average risk of breast cancer report screen-detection cancer rates and/or interval cancer rates. Syntheses the results to assess the overall impact that the shift from SFM to FFDM has had on screen-detection rates and interval rates. We are also comparing changes in measurements of: Positive predictive values: Proportion of women with a positive screening examination who are diagnosed with breast cancer Recall rates: Number of women with a positive screening examination per 1000 screened women False positive recall rate: Number of women with a positive screening examination who are not diagnosed with breast cancer per 1000 screened women Additional subgroup analyses examines the differences in screening frequency, age, breast density, and screening round. The University of Sydney Page 6

Search Updated: 18/03/18 MEDLINE (589) PREMEDLINE (47) PUBMED (579) EMBASE (853) NHSEED/DARE /COCHRANE (71) Reasons for exclusion Not SFD/FFDM (16) Not average risk (49) Repeat Data (43) No detection Rate (24) Insufficient information(7) Total Papers (2139) Deduplicated Title/Abstract (895) Full Text/Data Extraction (170) Duplicates (1244) Excluded (139) Included (31) The University of Sydney Page 7

Included Studies- by country Country Number of studies Years of Data Age Range Total number of screening Belgium 2 2001-2009 50-69 311,600 Canada 4 2007-2012 40-74 1,650,832 Finland 1 1999-2008 50-59 51,033 France 1 2008-2010 50-74 88,937 Ireland 1 2005-2007 50-64 188,823 Italy 2 2004-2012 45-74 116,206 Netherlands 1 2004-2011 50-74 7,343,327 Norway 3 1996-2010 45-69 1,864,972 Spain 5 1990-2012 45-69 4,445,390 Sweden 1 2000-2005 46-74 35,742 UK 3 2000-2010 40-70 107,844 United States 7 1997-2009 40-89 4,795,070 The University of Sydney Page 8

Forest plot of difference in film vs digital screendetection rates by country Screen-detected rate difference: 0.5 (CI:0.2 to 0.07) per 1000 women The University of Sydney Page 9

Included Studies with interval cancer Screen-detected cancer rate Interval cancer rate Film Digital Difference Film Digital Difference Belgium 5.2 5.9 0.7 2.7 2.8 0.0 Canada 4.9 5.0 0.1 1.6 1.6 0.1 Netherlands 5.3 6.3 0.9 2.2 2.2 0.0 Norway 5.6 5.2-0.4 1.8 2.0 0.2 Spain 4.2 4.3 0.1 1.4 1.4 0.0 United States 4.4 4.5 0.0 0.8 0.7-0.1 The University of Sydney Page 10

Forest plot of difference in film vs digital screendetection rates by country with interval rates Screen-detected rate difference: 0.3 (CI: -0.3 to 0.8) per 1000 women The University of Sydney Page 11

Forest plot of difference in film vs digital interval cancer rates Interval rate difference: -0.2 (CI: -0.5 to 0.2) per 1000 The University of Sydney Page 12

Difference in interval rate per 1000 women Difference in film vs digital in included studies with interval cancers Norway Underdiagnosis Canada Spain Belgium 0.0 Netherlands -0.6-0.4-0.2 0.0 0.2 0.4 0.6 0.8 1.0 Overdiagnosis 0.2 0.2 0.1 0.1 United States -0.1-0.1 Overdiagnosis Underdiagnosis Difference in screen-detected rate per 1000 women The University of Sydney Page 13

Conclusion Overall there has been a small increase in screen-detected cancers with the transition from film to digital mammography screening The effect of this practice shift on interval cancers remains unclear Reinforces the need to assess these effects for future changes such as 3D mammography Broader aim to establish a methodological framework and model to be used for assessing future changes in cancer screening programs The University of Sydney Page 14

Thank you Co-authors and supervisors: Dr Katy Bell, Dr Kevin McGeechan, Professor Nehmat Houssami, Professor Alexandra Barratt The University of Sydney Page 15